ArticleGynecologic oncology reports2024
Metastatic squamous cell carcinoma arising from mature teratoma of the ovary: Description of multi-modality treatment including incorporation of adjuvant immunotherapy and maintenance PARP inhibitor therapy.
Article in Gynecologic oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ovarian squamous cell carcinoma: clinicopathological features, prognosis and immunotherapy outcomes.Journal of gynecologic oncology · 2025Article
- Immunotherapy in young adults with mature cystic ovarian Teratoma-Derived squamous cell carcinoma: a case series.Journal of ovarian research · 2025Article
- A rare case of malignant transformation: squamous cell carcinoma arising on the basis of an ovarian mature cystic teratoma.BMC women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
•Squamous cell carcinoma arising from mature teratoma of the ovary is a rare occurrence without clear agreement regarding optimal treatment.•Multimodality treatment should be considered, particularly for metastatic disease.•Maintenance therapy may be considered.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.